BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21158921)

  • 1. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients.
    Vallin M; Guillaud O; Morard I; Gagnieu MC; Mentha G; Adham M; Morelon E; Boillot O; Giostra E; Dumortier J
    Clin Transplant; 2011; 25(4):660-9. PubMed ID: 21158921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ; Garbade J; Bittner HB; Fiedler M; Dhein S; Thiery J; Mohr FW; Gummert JF
    Int Immunopharmacol; 2006 Dec; 6(13-14):2011-7. PubMed ID: 17161355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis.
    Saliba F; Dharancy S; Lorho R; Conti F; Radenne S; Neau-Cransac M; Hurtova M; Hardwigsen J; Calmus Y; Dumortier J
    Liver Transpl; 2011 Aug; 17(8):905-13. PubMed ID: 21384525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
    Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC; Johnson SR; Mandelbrot DA; Pavlakis M; Horwedel T; Karp SJ; Egbuna O; Rodrigue JR; Chudzinski RE; Goldfarb-Rumyantzev AS; Hanto DW; Curry MP
    Clin Transplant; 2009; 23(6):887-96. PubMed ID: 19681971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications and management of everolimus after liver transplantation.
    Bilbao I; Sapisochin G; Dopazo C; Lazaro JL; Pou L; Castells L; Caralt M; Blanco L; Gantxegi A; Margarit C; Charco R
    Transplant Proc; 2009; 41(6):2172-6. PubMed ID: 19715864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.